Ta Hsung Tung

Array ( [id] => 9831678 [patent_doc_number] => 08940491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-27 [patent_title] => 'Genotoxicity as a biomarker for inflammation' [patent_app_type] => utility [patent_app_number] => 14/255882 [patent_app_country] => US [patent_app_date] => 2014-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 35 [patent_no_of_words] => 17426 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14255882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9812041 [patent_doc_number] => 20150023986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-22 [patent_title] => 'Modulation of Tim Receptor Activity in Combination with Cytoreductive Therapy' [patent_app_type] => utility [patent_app_number] => 14/250250 [patent_app_country] => US [patent_app_date] => 2014-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 23930 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14250250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11766956 [patent_doc_number] => 09375475 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-06-28 [patent_title] => 'Combination immunotherapy for the treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/250272 [patent_app_country] => US [patent_app_date] => 2014-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 11192 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14250272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10945723 [patent_doc_number] => 20140348743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1)' [patent_app_type] => utility [patent_app_number] => 14/248462 [patent_app_country] => US [patent_app_date] => 2014-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 58 [patent_no_of_words] => 50122 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14248462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10911697 [patent_doc_number] => 20140314714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'IMMUNOPOTENTIATIVE COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/245692 [patent_app_country] => US [patent_app_date] => 2014-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13976 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14245692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11778210 [patent_doc_number] => 09387247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-12 [patent_title] => 'Monoclonal antibodies to programmed death 1 (PD-1)' [patent_app_type] => utility [patent_app_number] => 14/244405 [patent_app_country] => US [patent_app_date] => 2014-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 100 [patent_no_of_words] => 50098 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 599 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14244405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9661728 [patent_doc_number] => 08808700 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2014-08-19 [patent_title] => 'Use of TNF alpha inhibitor for treatment of erosive polyarthritis' [patent_app_type] => utility [patent_app_number] => 14/228791 [patent_app_country] => US [patent_app_date] => 2014-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 22478 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14228791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9634314 [patent_doc_number] => 20140212422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-31 [patent_title] => 'METHODS FOR TREATING CANCER USING ANTI-PD-1 ANTIBODIES IN COMBINATION WITH ANTI-CTLA-4 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/227733 [patent_app_country] => US [patent_app_date] => 2014-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 58 [patent_no_of_words] => 50149 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14227733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771161 [patent_doc_number] => 20140294824 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'ANTIBODIES THAT BIND TO OX40 AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 14/222421 [patent_app_country] => US [patent_app_date] => 2014-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 32136 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14222421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9656310 [patent_doc_number] => 20140227315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-14 [patent_title] => 'Novel Chimeric Proteins and Methods for Using The Same' [patent_app_type] => utility [patent_app_number] => 14/215436 [patent_app_country] => US [patent_app_date] => 2014-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11682 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14215436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11873611 [patent_doc_number] => 09745368 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-29 [patent_title] => 'Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy' [patent_app_type] => utility [patent_app_number] => 14/214824 [patent_app_country] => US [patent_app_date] => 2014-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 35 [patent_no_of_words] => 57668 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14214824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9596741 [patent_doc_number] => 20140193422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB' [patent_app_type] => utility [patent_app_number] => 14/211438 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 11969 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14211438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12326118 [patent_doc_number] => 09944690 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-17 [patent_title] => Methods for controlling T cell proliferation [patent_app_type] => utility [patent_app_number] => 14/210034 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 42540 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14210034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670896 [patent_doc_number] => 20160017040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/773334 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 54792 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14773334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10919110 [patent_doc_number] => 20140322129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/207878 [patent_app_country] => US [patent_app_date] => 2014-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 53282 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14207878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10678080 [patent_doc_number] => 20160024225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-28 [patent_title] => 'PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/776399 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16766 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14776399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11231025 [patent_doc_number] => 09458246 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-04 [patent_title] => 'Proteins specific for BAFF and B7RP1' [patent_app_type] => utility [patent_app_number] => 14/203123 [patent_app_country] => US [patent_app_date] => 2014-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 14650 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14203123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785231 [patent_doc_number] => 20140302052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'Combination Therapy to Enhance NK Cell Mediated Cytotoxicity' [patent_app_type] => utility [patent_app_number] => 14/198845 [patent_app_country] => US [patent_app_date] => 2014-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 4437 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14198845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670873 [patent_doc_number] => 20160017018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'HUMAN CTLA4 MUTANTS AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/773056 [patent_app_country] => US [patent_app_date] => 2014-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8878 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14773056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11263301 [patent_doc_number] => 09487587 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/196871 [patent_app_country] => US [patent_app_date] => 2014-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 13 [patent_no_of_words] => 28612 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14196871 [rel_patent_id] =>[rel_patent_doc_number] =>)